NASDAQ:ACER - Acer Therapeutics Stock Price, Forecast & News

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

Acer Therapeutics Inc (NASDAQ:ACER) posted its earnings results on Wednesday, November, 13th. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.57) by $0.05. View Acer Therapeutics' Earnings History.

Acer Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Acer Therapeutics.

5 equities research analysts have issued 12-month target prices for Acer Therapeutics' shares. Their forecasts range from $9.00 to $48.00. On average, they anticipate Acer Therapeutics' share price to reach $26.75 in the next twelve months. This suggests a possible upside of 532.4% from the stock's current price. View Analyst Price Targets for Acer Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Acer Therapeutics.

News headlines about ACER stock have trended very positive recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Acer Therapeutics earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Acer Therapeutics.

Acer Therapeutics saw a drop in short interest in the month of December. As of December 31st, there was short interest totalling 442,900 shares, a drop of 8.8% from the December 15th total of 485,900 shares. Based on an average daily trading volume, of 49,800 shares, the days-to-cover ratio is presently 8.9 days. Approximately 9.1% of the company's shares are short sold. View Acer Therapeutics' Current Options Chain.

Some companies that are related to Acer Therapeutics include Corvus Pharmaceuticals (CRVS), TAIWAN LIPOSOME/S (TLC), Harrow Health (HROW), Tyme Technologies (TYME), ContraFect (CFRX), Evelo Biosciences (EVLO), Aldeyra Therapeutics (ALDX), Akorn (AKRX), Aptinyx (APTX), Agile Therapeutics (AGRX), Xeris Pharmaceuticals (XERS), NuCana (NCNA), Adamas Pharmaceuticals (ADMS), Galectin Therapeutics (GALT) and Mustang Bio (MBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Sarepta Therapeutics (SRPT), Synergy Pharmaceuticals (SGYP), NovaBay Pharmaceuticals (NBY), Novavax (NVAX), Arena Pharmaceuticals (ARNA), Madrigal Pharmaceuticals (MDGL), NVIDIA (NVDA), Actinium Pharmaceuticals (ATNM), Advanced Micro Devices (AMD) and Amarin (AMRN).

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ACER stock can currently be purchased for approximately $4.23.

Acer Therapeutics has a market capitalization of $42.70 million. The biopharmaceutical company earns $-21,280,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Acer Therapeutics employs 23 workers across the globe.View Additional Information About Acer Therapeutics.

The official website for Acer Therapeutics is http://www.acertx.com/.

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]